Pharmaceutical Licensing Overview: Risk-Aversion Breeds Creativity as Externalization Intensifies

Jan. 10, 2012 - PRLog -- Venture Planning Group (www.VPGMarketResearch.com), an international publishing and management consulting firm, is pleased to announce the completion of a new  pharmaceutical report, "Pharmaceutical Licensing Overview: Risk-Aversion Breeds Creativity as Externalization Intensifies."
(http://www.vpgmarketresearch.com/search.html?keyword=licensing+overview). The report provides industry executives with strategically significant competitor information and analysis of the overview of Big Pharma's current and anticipated future reliance on externally sourced products

Scope

•Overview of Big Pharma's current and anticipated future reliance on externally sourced products
•Overview of drivers and resistors of licensing deals and an assessment of key trends and factors that will shape the future make-up of licensing
•Analysis of key product deals during 2008-09, analyzing trends for in-licensing, out-licensing and manufacturing/supply arrangements
•Assessment of drug discovery and technology deals made by the top 10 pharmaceutical companies during 2008-09
Highlights

The number of in-licensing deals in 2009 increased by 12% over 2008, confirming that Big Pharma is actively seeking acquisitions and licensing agreements as a more cost-effective means of gaining access to novel products than carrying out extensive in-house R&D.

Although deals for drugs at the earliest stages of development accounted for almost 60% of all product in-licensing deals analyzed, Big Pharma greatly increased its focus on Phase II and III products in 2009 as it looks to offset the 2011 patent cliff by incorporating more advanced-stage products into its pipelines to enhance short/mid-term growth.

GlaxoSmithKline was by far the most active Big Pharma player. While many of its Big Pharma peers have participated in large M&A deals over the past 2 years, GlaxoSmithKline has thus far preferred to focus on incorporating externally acquired products into its pipeline.

To review or order this report, please visit
http://www.vpgmarketresearch.com/Pharmaceutical-Licensing...

To review related reports, please visit
http://www.VPGMarketResearch.com

Contact
Diagnostic Industry Market Research
Robert Fisher
robert@vpgcorp.com
+1 212 564 2838

# # #

Venture Planning Group is an international market research, publishing and management consulting firm, providing syndicated and custom services to corporate executives and key decision-makers in the Diagnostics, Pharmaceutical, Imaging, Orthopedics, Biotechnology, Chemical, Flavors & Fragrances, Food & Beverage, Electronics, and other industries.

During numerous proprietary single-client consulting assignments and over 500 multiclient studies, VPG has developed an extensive database on various industries, technologies, markets, companies, products, and executives worldwide.

VPG has served over 1,000 corporations in 70 countries, and has established a broad network of worldwide contacts with industry executives, opinion leaders, and experts from leading universities, research centers, the financial community and the government.

Specialties
Market Intelligence Surveys, Opportunity Analyses, New Technology/Product Assessments, Acquisition/Joint Venture Evaluations.